生脈生物科技股份有限公司
There are more than 7,000 orphan diseases in existence today, and yet only about 5% of them have treatment available. We recognize the tremendous unmet medical needs and a real opportunity to make a meaningful difference in the lives of these patients and families. As such, LifeMax dedicates itself to the development of first-in-class or best-in-class therapeutics for orphan diseases. Through licensing and collaboration, we have built a robust and science-driven portfolio that addresses critical unmet medical needs for the treatment of orphan diseases. We continue to expand the pipeline with a focus on modalities that target the underlying genetic cause. With its robust pipeline and seasoned management team, LifeMax is well positioned to grow into a leader in the development and commercialization of novel orphan drugs.
登入
